Canopy Growth (CGC) Current Deferred Revenue (2017 - 2018)
Canopy Growth (CGC) reported Current Deferred Revenue of $712083.7 for Q1 2018, up 60.32% on a YoY basis from $444159.3 in Q1 2017, and up 60.32% sequentially from $444159.3 in Q1 2017.
Canopy Growth (CGC) Current Deferred Revenue (2017 - 2018) Analysis & Trends
Canopy Growth (CGC) has 2 years of Current Deferred Revenue data on file, last reported at $712083.7 in Q1 2018.
- For the quarter ending Q1 2018, Current Deferred Revenue rose 60.32% year-over-year to $712083.7; the trailing twelve-month figure through Mar 2018 stood at $712083.7 (up 60.32% YoY), and the FY2018 full-year result was $701742.9, up 56.61% from the prior year.
- Current Deferred Revenue climbed to $712083.7 in Q1 2018, from $444159.3 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $712083.7 in Q1 2018 to a low of $444159.3 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 712,083.71 |
| Mar 31, 2017 | 444,159.35 |